Breakthrough Therapies Driving the X-Linked Hypophosphatemia Market Forward According to a newly published market research report by 24LifeSciences, the global X-linked hypophosphatemia market was valued at USD 26.9 million in 2026 and is projected to reach USD 31.2 million by 2034, growing at a compound annual growth rate (CAGR) of 2.2% during the forecast period. X-linked hypophosphatemia (XLH), also known as vitamin D-resistant rickets, is a rare, inherited disorder characterized by renal phosphate wasting and impaired bone mineralization. This condition stems from mutations in the PHEX gene, leading to elevated levels of the hormone fibroblast growth factor 23 (FGF23), which disrupts phosphate reabsorption in the kidneys and reduces active vitamin D synthesis. The disease manifests through skeletal deformities, growth retardation, bone pain, and dental abnormalities, presenting a lifelong management challenge for patients and healthcare systems. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8996/x-linked-hypophosphatemia-market

Rising GI Disorders Driving the Malabsorption Syndrome Market Worldwide According to a newly published market research report by 24LifeSciences, global malabsorption syndrome market value is at USD 8.5 billion in 2026 and is projected to reach USD 13.2 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.4% during the forecast period. Malabsorption syndrome encompasses a group of disorders where the small intestine is unable to properly absorb sufficient amounts of critical nutrients and fluids from ingested food, leading to deficiencies in macronutrients like proteins, carbohydrates, and fats, as well as vital micronutrients including essential vitamins and minerals. This complex condition, often arising secondary to chronic gastrointestinal diseases, demands a multifaceted therapeutic approach that combines targeted pharmaceuticals with specialized nutritional support, underlining its significant clinical and economic impact on global healthcare systems. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9520/malabsorption-syndrome-market

FibroTouch Devices Market Size to Reach USD 220 Million by 2032 | Growth Insights Global FibroTouch Devices market is undergoing steady expansion as healthcare systems increasingly prioritize non-invasive diagnostics for liver disease management. Valued at USD 120 million in 2024, the market is projected to grow from USD 132 million in 2025 to USD 220 million by 2032, registering a CAGR of 7.8% during the forecast period. This growth reflects a structural shift away from invasive liver biopsies toward faster, safer, and more patient-friendly elastography-based solutions that deliver real-time clinical insights. The FibroTouch Devices market is gaining prominence across hospitals, diagnostic centers, and specialty clinics as chronic liver conditions such as NAFLD, viral hepatitis, and alcoholic liver disease continue to rise globally. Increasing disease awareness, early screening initiatives, and technological refinements are positioning FibroTouch as a core diagnostic modality in modern hepatology workflows. Access the market report https://www.24lifesciences.com/fibrotouch-devices-market-9969

Tardive Dyskinesia Treatment Market Size to Reach USD 1.3 Billion by 2032 | Growth Insights Global Tardive Dyskinesia Treatment market is undergoing a notable transformation as healthcare systems prioritize early diagnosis, neurological specialization, and precision pharmacotherapy. Valued at USD 643.5 million in 2024, the market is projected to grow from USD 720.6 million in 2025 to USD 1.3 billion by 2032, expanding at a CAGR of 9.2% during the forecast period. Rising awareness of movement disorders, increased use of long-term antipsychotic therapies, and the growing adoption of FDA-approved VMAT2 inhibitors are central to this sustained growth trajectory. Access the market report https://www.24lifesciences.com/tardive-dyskinesia-treatment-market-10341

Mendelian Disorders Testing Market Size to Reach USD 7.8 Billion by 2032 | Growth Trends & Insights Global Mendelian disorders testing market is gaining strong momentum as healthcare systems worldwide intensify their focus on early diagnosis, preventive screening, and precision medicine. The market is projected to expand from USD 4.6 billion in 2025 to USD 7.8 billion by 2032, registering a robust compound annual growth rate (CAGR) of 7.8% during the forecast period. This sustained growth reflects rising awareness of inherited diseases, expanding newborn and prenatal screening programs, and rapid advancements in genomic testing technologies. Access the market report https://www.24lifesciences.com/mendelian-disorders-testing-market-9526

Metabolic Biomarker Testing Market Size to Reach USD 22.8 Billion by 2032 | Growth Trends & Forecasts Global metabolic biomarker testing market is experiencing robust growth as healthcare systems increasingly prioritize precision diagnostics, early disease detection, and individualized treatment strategies. Valued at USD 11.3 billion in 2024, the market is expected to expand from USD 12.5 billion in 2025 to USD 22.8 billion by 2032, registering a Compound Annual Growth Rate (CAGR) of 8.7% during the forecast period. This strong trajectory highlights the growing clinical and commercial importance of metabolic biomarkers in modern healthcare and life sciences. Access the market report https://www.24lifesciences.com/metabolic-biomarker-testing-market-9530

Pigmentation Disorder Therapeutic Market Size to Reach USD 8.75 Billion by 2032 Global pigmentation disorder therapeutic market is witnessing steady and resilient growth as dermatological care increasingly integrates medical necessity with aesthetic demand. Valued at USD 6.11 billion in 2024, the market is projected to expand from USD 6.44 billion in 2025 to USD 8.75 billion by 2032, registering a CAGR of 5.4% during the forecast period. This growth reflects rising awareness of skin disorders, improved access to dermatology services, and continuous innovation in topical and procedural treatment options across both developed and emerging healthcare systems. Access the complete report https://www.24lifesciences.com/pigmentation-disorder-therapeutic-market-9224

Pancreatic Cancer Diagnostic Market to Grow Rapidly by 2032 According to a new report from Intel Market Research, Global Pancreatic Cancer Diagnostic market was valued at USD 1.95 billion in 2024 and is projected to reach USD 3.12 billion by 2032, growing at a steady CAGR of 6.5% during the forecast period. This expansion comes at a crucial time when pancreatic cancer remains one of the most challenging malignancies to detect early, driving urgent demand for innovative diagnostic solutions across healthcare systems worldwide.